RecruitingNot ApplicableNCT06159140

Small Vessel Diseases: Ultra-realistic Microstructure Computational Model to Refine Individual Treatment


Sponsor

University Hospital, Tours

Enrollment

20 participants

Start Date

Mar 26, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

Small vessel disease (SVD) accounts for 25% of strokes and is the second most common cause of dementia after Alzheimer's disease. Unlike other causes of stroke, SVD manifests itself years before the stroke by the accumulation of tissue damage. Although heterogeneous, these lesions appear on Magnetic Resonance Imaging (MRI) as white matter hypersignals (WMH). In this context, the ANR SUMMIT project will characterize these lesions in vivo to develop new markers in the early stages of stroke. It is subdivided into 4 work packages, the third one being promoted by CHRU de Tours.


Eligibility

Min Age: 82 YearsMax Age: 100 Years

Inclusion Criteria1

  • Prior Enrollement in Tours body donation program Age ≥ 82 years Able to remain supine in the MR scanner for acquisition (duration 60-minutes) Affiliation to social security Informed and written consent

Exclusion Criteria1

  • Contraindications to body donation, especially infectious disease (VIH, HBV…) Contraindications to MRI

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEMRI

In vivo MRI


Locations(1)

UHT of Tours

Tours, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06159140


Related Trials